Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU-001 in dominantly inherited Alzheimer's disease
NL-OMON44417Phase 3Withdrawn
- Sponsor
- IQVIA
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gantenerumab, solanezumab and atabecestat in Alzheimer's disease (AD) (4 arms), sponsored by IQVIA. Primary endpoints: Rate of progression on the DIAN-TU cognitive composite and DIAN-TU cognitive composite components. Planned start Dec 2017; status: withdrawn.
02
Drugs
gantenerumabsolanezumabatabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON44417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44417.